Showing results (971-980 of 2,107) with videos related to

Sort By:
Pageof 211
CNS Drugs|July 26, 2024
Caregiver Perspective of Benefits and Side Effects of Anti-Seizure Medications in CDKL5 Deficiency Disorder from an International DatabaseKingsley Wong, Mohammed Junaid, Solomon Alexander, et al.
CNS Drugs|July 11, 2024
Patterns of Pregabalin Users from Substance Abuse Treatment Facilities: Results from the French OPPIDUM Program from 2008 to 2022Clément Garnier, Martin Schein, Clémence Lacroix, et al.
CNS Drugs|May 1, 2024
Sex Differences in Adverse Effects of Antiseizure Medications in Adults with Epilepsy: A Systematic ReviewLoretta Giuliano, Vania Durante, Giulia Battaglia, et al.
CNS Drugs|June 5, 2024
Semi-physiological Pharmacokinetic Model of Clozapine and Norclozapine in Healthy, Non-smoking Volunteers: The Impact of Race and GeneticsOrwa Albitar, Sabariah Noor Harun, Siti Maisharah Sheikh Ghadzi
CNS Drugs|May 29, 2024
Effectiveness of Anti-Calcitonin Gene-Related Peptide Medication in Vestibular Migraine: A Retrospective Cohort Study in an Asian PopulationTeppei Kouga, Toru Miwa, Kishiko Sunami, et al.
CNS Drugs|April 13, 2024
Impulse Control Disorders in Parkinson's Disease: An Overview of Risk Factors, Pathogenesis and Pharmacological ManagementFederico Carbone, Atbin Djamshidian
CNS Drugs|April 10, 2024
Oral Delta-9-Tetrahydrocannabinol (THC) Increases Parasympathetic Activity and Supraspinal Conditioned Pain Modulation in Chronic Neuropathic Pain Male Patients: A Crossover, Double-Blind, Placebo-Controlled TrialLibat Weizman, Haggai Sharon, Lior Dayan, et al.
CNS Drugs|January 17, 2026
Safety and Efficacy of Monoamine Oxidase Inhibitors in Patients Who Use Psychoactive Substances: Potential Drug Interactions and Substance Use Disorder Treatment DataGaëlle Rached, Anna Campana, Dimitri Fiani, et al.
CNS Drugs|November 21, 2025
Effects of Long-Term Treatment with TV-46000 on Symptom Improvement Over Time in Stabilized Patients with SchizophreniaJohn M Kane, Orna Tohami, Kelli R Franzenburg, et al.
CNS Drugs|December 1, 2025
Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer's Disease: Synthesis of Evidence from Observational and Interventional TrialsSusan Abushakra, P Murali Doraiswamy, John A Hey, et al.
Pageof 211